Cartesian Therapeutics, Inc.RNACNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-36.70%
↓ 270% below average
Average (9y)
21.64%
Historical baseline
Range
High:119.15%
Low:-36.70%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | -36.70% |
| 2023 | -1.54% |
| 2022 | 5.30% |
| 2021 | 26.11% |
| 2020 | 27.52% |
| 2019 | -10.37% |
| 2018 | 5.58% |
| 2017 | 52.06% |
| 2016 | 29.25% |
| 2015 | 119.15% |